Global Antiplatelet Drugs Market Research Report 2021

Antiplatelet drugs are wrongly referred to as the blood thinning drugs. They don’t thin the blood but instead interfere with the important process by which blood clots. Antiplatelet agent normally decrease the clumping of blood cells thereby decreasing the potentially harmful blood clots. People who are at high risk of heart disease when given antiplatelet agents, their risks of strokes and heart attacks can be avoided.
The antiplatelet drug market is expected to propel during the forecast period owing to the increasing organic and inorganic growth taking place within the industry. Moreover, the market for generic is also at a rise thereby giving a boost to the generic antiplatelet drug manufacturers. The amount of money which the companies are spending towards research and development is also expected to contribute towards the revenue of the antiplatelet drugs market in the future. For instance in February 2017, PLx Pharma announced positive antiplatelet data for its Aspertec drug which was published in the Journal of the American College of Cardiology (JACC). Now researchers are concentrating on analyzing the pharmacodynamics and meta-analyses to determine whether one drug has an edge over other.

The global Antiplatelet Drugs market was valued at US$ 1420.1 million in 2019 and is expected to reach US$ 1914.5 million by the end of 2026, growing at a CAGR of 4.3% during 2021-2026.
This report focuses on Antiplatelet Drugs volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Antiplatelet Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Antiplatelet Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Aspirin
Clopidogrel
Ticagrelor
Prasugrel
Dipyridamole
Ticlopidine
Abciximab
Tirofiban
Others

Segment by Application
Hospitals
Clinic
Emergency Service Centers
Ambulatory Surgical Centers
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
The Medicines Company
AstraZeneca
The Medicines Company
Portola Pharmaceuticals
Bayer Pharmaceuticals
Bristol-Myers Squibb Company
Boehringer Ingelheim Pharmaceuticals
Alta Laboratories
Shandong Xinhua Pharmaceutical
Sanis Health
Syntex
Hoffmann La Roche
Teva
Sandoz Canada Incorporated
Pharmascience
Mylan Pharmaceuticals